

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Qyuns Therapeutics Co., Ltd.**  
**江蘇荃信生物醫藥股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 2509)**

## **CHANGE OF ADDRESS OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG**

The board of directors (the “**Board**”) of Qyuns Therapeutics Co., Ltd. (the “**Company**”) hereby announces that with effect from January 10, 2025, the address of the principal place of business in Hong Kong of the Company will change to Room 1912, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong.

By order of the Board  
**Qyuns Therapeutics Co., Ltd.**  
**Mr. Qiu Jiwan**

*Chairman of the Board and Executive Director*

Hong Kong, January 10, 2025

*As at the date of this announcement, the Board of the Company comprises Mr. Qiu Jiwan as chairman of the Board and an executive director, Mr. Wu Yiliang and Mr. Lin Weidong as executive directors, Mr. Yu Xi and Mr. Wu Zhiqiang as non-executive directors, and Dr. Zou Zhongmei, Dr. Ling Jianqun and Mr. Fung Che Wai, Anthony as independent non-executive directors.*